This review summarizes current studies/molecular mechanisms regarding the association between the gut microbiota and the development of cancers, which provides insights into the therapeutic strategies that could be harnessed for cancer diagnosis, treatment or prevention.

This review discusses molecular traits and recent ER-low positive breast cancer innovations, highlighting molecular-targeted treatment rather than traditional unified endocrine therapy for future basic and clinical research.

The mechanisms of drug resistance are intricate and involve drug efflux, epithelial mesenchymal transition, DNA damage repair, and autophagy. Nano-delivery and self-cellular drug delivery platforms have a broad prospective for alleviating OSCC drug resistance. In particular, the combined application of new technologies (including CRISPR systems) opens up new horizons for treatment of OSCC drug resistance.

We constructed one of the largest ubiquitinome dataset obtained from human cancer tissues to date using the high-resolution mass spectrometry and immunoenrichment of diGly-modified peptides. We identified a E3 ligase, SYVN1, which potentially participated in the metastasis of HCC. We studied the interaction omics of SYVN1, and found it interacted with HSP90 and impacted the ubiquitination of EEF2K.

This 15-year longitudinal study described cancer burden of a rapid changing country with significant regional and urban-rural disparities, which is important in evaluating the effect of population ageing, risk factor exposure, and public health efforts on cancer mortality. Lung and liver cancers were the 1st leading cause of immature death in women and men, respectively. Lung, colorectal, and pancreatic cancers kept increasing in rural areas. These findings are references for policy making to control cancer.

The cancer spectrum of China is changing, with a rapidly increase incidence and burden of "cancers of the rich" (lung, breast, colorectal, and prostate cancer) in addition to a high incidence and heavy burden of “cancers of the poor” (liver, stomach, esophageal, and cervical cancer).